By Clinical Research Staff 

October 29, 2025 | Pangaea Data announces a collaboration with Microsoft; Ipsen acquires ImCheck Therapeutics; Flatiron Health released first-of-their-kind advances in LLM-extracted progression data and other uses; and more. 

Pangaea Data announced a collaboration with Microsoft with plans to connect Microsoft Dragon Copilot with its clinical platform. The collaboration—which will bring Dragon Copilot’s natural language speech, ambient listening, and generative AI capabilities together with Pangaea Data’s advanced AI reasoning—is designed to help clinicians turn real-time patient conversations into actionable insights that lead to earlier intervention and more personalized care. The collaboration aims to reduce diagnosis time, giving patients more timely and guideline-directed treatments, better outcomes, and less pressure on health systems. Press release.

Pangaea also launched its next-generation platform, which is designed to help clinicians close care gaps, find untreated and sub-optimally treated patients, and drive real improvement in patient outcomes, all with reduced costs and increased revenues for health systems. Pangaea’s platform has been deployed across 13 countries and uses proven capabilities to flag patients who are missing for appropriate screening or treatments, despite relevant data being present in their records. This will enable earlier diagnosis and more effective triaging of hard-to-diagnose conditions, as well as helping health systems deliver more efficient care for better patient outcomes. Press release.

Ipsen and ImCheck Therapeutics have entered a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics. The anticipated acquisition is focused on the lead Phase I/II program ICT01 in first line acute myeloid leukemia (AML)3 patients who are ineligible for intensive chemotherapy. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer and received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025. Press release.

Critical Path Institute (C-Path) officially launched the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD). CP-DMC is being established with Quinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical trial and real-world data at scale for model development and application. The models are designed to transform integrated longitudinal datasets into actionable quantitative descriptions of disease trajectories, treatment response, and variability in pediatric populations. They will serve as reusable platforms that reduce patient burden and strengthen evidence generation across programs. Press release.

Flatiron Health released first-of-their-kind advances in LLM-extracted progression data, data quality frameworks, and harmonized multinational datasets transform cancer research capabilities. One of them is the Validation of Accuracy for LLM/ML-Extracted Information and Data Framework, which examines performance metrics, data usability, and the ability to replicate expected findings, with a key component being benchmarking performance against expert human abstraction. Another is the Trusted Research Environment, which enabled secure access to patient-level data at scale and harmonized data across the U.K., Germany, Japan, and other markets. Press release.

Dash Solutions announced the launch of dashClinical, formally branding its enhanced payment solution that delivers secure, real-time payments to clinical trial participants worldwide. The launch includes both technological updates and strategic senior hires to better support the company’s global customer base of sponsors, site networks, clinical research organizations, and CTMS platforms, now spanning 80 countries and continuing to expand. Press release. 

eClinical Solutions has entered a strategic partnership with ZS to deliver an enhanced risk-based quality management (RBQM) offering. The collaboration pairs eClinical’s elluminate Clinical Data Cloud, the AI-powered clinical data infrastructure and analytics platform, with ZS’s proven RBQM consulting and custom-built RBQM solution expertise. eClinical Solutions and ZS will provide sponsors a unified experience designed to transform how organizations manage risks, ensure quality, and drive trial efficiency. Press release. 

The START Center for Cancer Research (START), its preclinical division XenoSTART, and Minerva Imaging announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development. This collaboration unites XenoSTART's repository of clinically annotated patient-derived xenograft models with Minerva Imaging's advanced molecular imaging and radionuclide therapy expertise, creating a single-source solution spanning discovery, translational research, and manufacturing. Press release.